Skip to content
Preprint · OA via OpenAlex

Rapamycin and Alzheimer’s disease: Time for a clinical trial?

Matt R. Kaeberlein, Verónica Galván

Science Translational Medicine · 2019 · ▲ 171 citations

Abstract

The drug mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1126/scitranslmed.aar4289
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Kaeberlein, M.R., &amp; Galván, V. (2019). Rapamycin and Alzheimer’s disease: Time for a clinical trial?. <em>Science Translational Medicine</em>. https://doi.org/10.1126/scitranslmed.aar4289
Vancouver
Kaeberlein MR, Galván V. Rapamycin and Alzheimer’s disease: Time for a clinical trial?. Science Translational Medicine. 2019. doi:10.1126/scitranslmed.aar4289.
BibTeX
@unpublished{matt2019Rapamy, title = {Rapamycin and Alzheimer’s disease: Time for a clinical trial?}, author = {Matt R. Kaeberlein and Verónica Galván}, journal = {Science Translational Medicine}, year = {2019}, doi = {10.1126/scitranslmed.aar4289}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings